{"id":"cetuximab-concomitant-boost-radiotherapy","safety":{"commonSideEffects":[{"rate":"80–90","effect":"Acneiform rash"},{"rate":"70–85","effect":"Radiation dermatitis"},{"rate":"60–75","effect":"Mucositis"},{"rate":"50–70","effect":"Dysphagia"},{"rate":"3–5","effect":"Infusion reactions"},{"rate":"25–55","effect":"Hypomagnesemia"},{"rate":"20–30","effect":"Diarrhea"}]},"_chembl":null,"_fixedAt":"2026-03-30T13:47:34.054241","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cetuximab is a chimeric monoclonal antibody that binds to EGFR and prevents ligand-induced receptor activation, blocking downstream proliferation and survival pathways. When administered concomitantly with boost radiotherapy (higher focal doses of radiation), cetuximab sensitizes tumor cells to radiation damage, potentially through inhibition of DNA repair mechanisms and radiosensitization of EGFR-expressing malignancies.","oneSentence":"Cetuximab blocks epidermal growth factor receptor (EGFR) signaling to inhibit tumor cell growth, and when combined with concomitant boost radiotherapy, enhances radiation-induced cell death in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:05:24.124Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Locally advanced head and neck squamous cell carcinoma (in combination with concomitant boost radiotherapy)"},{"name":"Oropharyngeal cancer"}]},"_fixedFields":["pubmed(2)"],"trialDetails":[{"nctId":"NCT02999087","phase":"PHASE3","title":"Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2017-09-14","conditions":"HNSCC","enrollment":707},{"nctId":"NCT03532737","phase":"PHASE2","title":"Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer","status":"UNKNOWN","sponsor":"Kuwait Cancer Control Center","startDate":"2018-10-07","conditions":"Locally Advanced Head and Neck Cancer","enrollment":50},{"nctId":"NCT03001570","phase":"PHASE2","title":"Accelerated Modulated Fractionation (SIB-IMRT) for Head and Neck District","status":"UNKNOWN","sponsor":"European Institute of Oncology","startDate":"2014-01","conditions":"Carcinoma of the Head and Neck","enrollment":10},{"nctId":"NCT00265941","phase":"PHASE3","title":"Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2005-11","conditions":"Head and Neck Cancer","enrollment":940},{"nctId":"NCT01884259","phase":"PHASE2","title":"Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN","status":"COMPLETED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2013-05","conditions":"Squamous Cell Carcinoma of the Hypopharynx Stage III, Squamous Cell Carcinoma of the Hypopharynx Stage IV, Squamous Cell Carcinoma of the Larynx Stage III","enrollment":100},{"nctId":"NCT00468169","phase":"PHASE2","title":"Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2006-07","conditions":"Head and Neck Cancer","enrollment":110},{"nctId":"NCT01216020","phase":"PHASE2","title":"Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer","status":"TERMINATED","sponsor":"Azienda USL 4 Prato","startDate":"2010-10","conditions":"Head and Neck Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms","enrollment":70},{"nctId":"NCT01012258","phase":"PHASE3","title":"Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2009-02","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":70},{"nctId":"NCT00865098","phase":"PHASE2","title":"Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2009-03","conditions":"Carcinoma of the Head and Neck","enrollment":27},{"nctId":"NCT00004227","phase":"PHASE3","title":"Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"1999-04","conditions":"Head and Neck Cancer","enrollment":32},{"nctId":"NCT00941135","phase":"PHASE2","title":"Safety and Efficacy Study in Patients With Local Advanced Larynx/Hypolarynx Carcinoma Treated With TPF Induction Chemotherapy Followed by Hyperfractionated Radiotherapy With Cetuximab","status":"TERMINATED","sponsor":"Fundacion Miguel Servet","startDate":"2009-05","conditions":"Laryngeal Neoplasms","enrollment":70},{"nctId":"NCT00251381","phase":"PHASE2","title":"Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.","status":"UNKNOWN","sponsor":"Trial Form Support S.L.","startDate":"2005-11","conditions":"Oropharyngeal Neoplasms","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"recentPublications":[{"date":"2013 May","pmid":"23479383","title":"Phase II study of cetuximab plus concomitant boost radiotherapy in Japanese patients with locally advanced squamous cell carcinoma of the head and neck.","journal":"Japanese journal of clinical oncology"},{"date":"2006 Mar 1","pmid":"16505426","title":"Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Erbitux®"],"phase":"phase_3","status":"active","brandName":"Cetuximab + concomitant boost radiotherapy","genericName":"Cetuximab + concomitant boost radiotherapy","companyName":"Merck KGaA, Darmstadt, Germany","companyId":"merck-kgaa-darmstadt-germany","modality":"Biologic","firstApprovalDate":"","aiSummary":"Cetuximab blocks epidermal growth factor receptor (EGFR) signaling to inhibit tumor cell growth, and when combined with concomitant boost radiotherapy, enhances radiation-induced cell death in cancer cells. Used for Locally advanced head and neck squamous cell carcinoma (in combination with concomitant boost radiotherapy), Oropharyngeal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}